SRPRA: A Protein Targeted for Neurodegenerative Diseases (G6734)

Target Name: SRPRA

NCBI ID: G6734

SRPRA

SRPRA: A Protein Targeted for Neurodegenerative Diseases

SRPRA (sulfate dimethyl ester acid) is a protein that is expressed in the brain and is known for its role in the regulation of cell death and the development of neurodegenerative diseases. It is also a drug target (or biomarker) that has been identified by researchers and is being targeted for development as a new treatment for various neurological disorders.

SRPRA is a member of the superfamily of proteins known as the pro-inflammatory receptor protein (PARP) family. These proteins are involved in the regulation of cellular responses to stress and are thought to play a role in the development of neurodegenerative diseases.

SRPRA is expressed in the brain and is involved in the regulation of cell death, as well as the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. It is thought to play a role in the production of reactive oxygen species (ROS), which can damage cells and contribute to the development of neurodegenerative diseases.

SRPRA is also involved in the regulation of cellular signaling pathways, including the production of neurotransmitters such as dopamine and serotonin. It is thought to play a role in the development of neurotransmitter dysfunction, which can be a symptom of neurodegenerative diseases.

SRPRA is a potential drug target (or biomarker) because of its involvement in the regulation of cell death and the development of neurodegenerative diseases. Researchers are currently studying the potential mechanisms of SRPRA as a drug target, with the goal of developing new treatments for neurodegenerative diseases.

One way that SRPRA is being targeted as a drug target is through its role in the production of ROS. Researchers have found that SRPRA is involved in the production of ROS, which can damage cells and contribute to the development of neurodegenerative diseases.

Another way that SRPRA is being targeted as a drug target is through its role in the regulation of cellular signaling pathways. Researchers have found that SRPRA is involved in the production of neurotransmitters such as dopamine and serotonin, which are important for the functioning of neurons.

SRPRA is also being studied as a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. Researchers have found that SRPRA is expressed in the brain and is involved in the regulation of cell death and the development of neurodegenerative diseases.

In conclusion, SRPRA is a protein that is expressed in the brain and is involved in the regulation of cell death and the development of neurodegenerative diseases. It is also a potential drug target (or biomarker) due to its involvement in the production of ROS and the regulation of cellular signaling pathways. Further research is needed to fully understand the role of SRPRA in the development of neurodegenerative diseases and to develop new treatments for these disorders.

Protein Name: SRP Receptor Subunit Alpha

Functions: Component of the signal recognition particle (SRP) complex receptor (SR) (PubMed:16439358). Ensures, in conjunction with the SRP complex, the correct targeting of the nascent secretory proteins to the endoplasmic reticulum membrane system (PubMed:16675701, PubMed:34020957). Forms a guanosine 5'-triphosphate (GTP)-dependent complex with the SRP subunit SRP54 (PubMed:34020957). SRP receptor compaction and GTPase rearrangement drive SRP-mediated cotranslational protein translocation into the ER (PubMed:34020957)

The "SRPRA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRPRA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets